Fate Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.23 |
Market Cap |
$1.38 B |
Shares Outstanding |
65.19 M |
Public Float |
56.64 M |
Address |
3535 General Atomics Court San Diego California 92121 United States |
Employees | - |
Website | http://www.fatetherapeutics.com |
Updated | 07/08/2019 |
Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. The company products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. |